Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
Authors:
Open Access
- 3 September 2019
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 30 (11) , 1686-1688
Abstract
G Mountzios, J Remon, S Novello, N Blais, R Califano, T Cufer, A M Dingemans, S V Liu, N Peled, N A Pennell, M Reck, C Rolfo, D Tan, J Vansteenkiste, H West, BKeywords
Funding Information
- AstraZeneca (10.13039/100004325)
This publication has 16 references indexed in Scilit:
- KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.Journal of Clinical Oncology, 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2019
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of Clinical Oncology, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015